Publications

Publications for the team Oncostat

Titre Publication Type Publication year Auteur
A proposal for a new PhD level curriculum on quantitative methods for drug development journalArticle 2018 Jaki, T.; Gordon, A.; Forster, P.; Bijnens, L.; Bornkamp, B.; Brannath, W.; Fontana, R.; Gasparini, M.; Hampson, L. V.; Jacobs, T.; Jones, B.; Paoletti, X.; Posch, M.; Titman, A.; Vonk, R.; Koenig, F.
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort journalArticle 2018 Kandel, M.; Allayous, C.; Dalle, S.; Mortier, L.; Dalac, S.; Dutriaux, C.; Leccia, M. T.; Guillot, B.; Saiag, P.; Lacour, J. P.; Legoupil, D.; Lesimple, T.; Aubin, F.; Beylot-Barry, M.; Brunet-Possenti, F.; Arnault, J. P.; Granel-Brocard, F.; Stoebner, P. E.; Dupuy, A.; Maubec, E.; Grob, J. J.; Dreno, B.; Rotolo, F.; Ballon, A.; Michiels, S.; Lebbe, C.; Borget, I.
[Prostate brachytherapy: New techniques, new indications] journalArticle 2018 Blanchard, P.; Graff-Cailleaud, P.; Bossi, A.
Follow-up of differentiated thyroid cancer - what should (and what should not) be done journalArticle 2018 Lamartina, L.; Grani, G.; Durante, C.; Borget, I.; Filetti, S.; Schlumberger, M.
Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis journalArticle 2018 Guerrini-Rousseau, L.; Dufour, C.; Varlet, P.; Masliah-Planchon, J.; Bourdeaut, F.; Guillaud-Bataille, M.; Abbas, R.; Bertozzi, A. I.; Fouyssac, F.; Huybrechts, S.; Puget, S.; Bressac-De Paillerets, B.; Caron, O.; Sevenet, N.; Dimaria, M.; Villebasse, S.; Delattre, O.; Valteau-Couanet, D.; Grill, J.; Brugières, L.
Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking? journalArticle 2018 Bibault, J. E.; Blanchard, P.
Daily Biopsy Diagnosis in Surgical Pathology: Concordance Between Light Microscopy and Whole-Slide Imaging in Real-Life Conditions journalArticle 2018 Villa, I.; Mathieu, M. C.; Bosq, J.; Auperin, A.; Pomerol, J. F.; Lacroix-Triki, M.; Scoazec, J. Y.; Dartigues, P.
Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis journalArticle 2017 Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y.
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial journalArticle 2017 Desportes, E.; Wagner, M.; Kamal, M.; Salomon, A. V.; Deniziaut, G.; Pierron, G.; Rouleau, E.; Jouffroy, T.; Le Tourneau, C.; Paoletti, X.; Servois, V.
[Proton therapy for head and neck cancers] journalArticle 2017 Blanchard, P.; Frank, S. J.
Statistical approaches for evaluating body composition markers in clinical cancer research journalArticle 2017 Bayar, M. A.; Antoun, S.; Lanoy, E.
Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis journalArticle 2017 Chebib, R.; Verlingue, L.; Cozic, N.; Faron, M.; Burtin, P.; Boige, V.; Hollebecque, A.; Malka, D.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial journalArticle 2017 Desportes, E.; Wagner, M.; Kamal, M.; Salomon, A. V.; Deniziaut, G.; Pierron, G.; Rouleau, E.; Jouffroy, T.; Le Tourneau, C.; Paoletti, X.; Servois, V.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort journalArticle 2017 Blanchard, P.; Davis, J. W.; Frank, S. J.; Kim, J.; Pettaway, C. A.; Pugh, T. J.; Pisters, L. L.; Ward, J. F.; Choi, S.; Chapin, B. F.; Hoffman, K.; Navai, N.; Achim, M.; McGuire, S. E.; Matin, S. F.; Nguyen, Q.; Mahmood, U.; Graber, W. J.; Chen, H. C.; Wang, X.; Kuban, D. A.
Bayesian survival analysis in clinical trials: What methods are used in practice? journalArticle 2017 Brard, C.; Le Teuff, G.; Le Deley, M. C.; Hampson, L. V.
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study journalArticle 2017 Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial journalArticle 2017 Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C.
Letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?" journalArticle 2017 Hill, C.; Asselain, B.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
In Regard to Arthurs et al journalArticle 2017 Blanchard, P.; Garden, A. S.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial journalArticle 2017 Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification journalArticle 2017 Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study journalArticle 2017 Bredart, A.; Bodson, S.; Le Tourneau, C.; Flahault, C.; Bonnetain, F.; Beaudeau, A.; Coquan, E.; Dolbeault, S.; Paoletti, X.
Burnout among young European oncologists: a call for action journalArticle 2017 Blanchard, P.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
In Regard to Arthurs et al journalArticle 2017 Blanchard, P.; Garden, A. S.
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study) journalArticle 2017 Fresneau, Brice; Hackshaw, A.; Hawkins, D. S.; Paulussen, M.; Anderson, J. R.; Judson, I.; Litière, S.; Dirksen, U.; Lewis, I.; van den Berg, H.; Gaspar, N.; Gelderblom, H.; Whelan, J.; Boddy, A. V.; Wheatley, K.; Pignon, J. P.; De Vathaire, F.; Le Deley, M. C.; Le Teuff, G.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients journalArticle 2017 Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C.
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice journalArticle 2017 Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M.
The frequency of cancer in France: Most recent data and trends journalArticle 2017 Ribassin-Majed, L.; Le-Teuff, G.; Hill, C.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful? journalArticle 2017 Daroles, J.; Borget, I.; Suciu, V.; Mazouni, C.; Delaloge, S.; Balleyguier, C.
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort journalArticle 2017 Blanchard, P.; Davis, J. W.; Frank, S. J.; Kim, J.; Pettaway, C. A.; Pugh, T. J.; Pisters, L. L.; Ward, J. F.; Choi, S.; Chapin, B. F.; Hoffman, K.; Navai, N.; Achim, M.; McGuire, S. E.; Matin, S. F.; Nguyen, Q.; Mahmood, U.; Graber, W. J.; Chen, H. C.; Wang, X.; Kuban, D. A.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.